TY - JOUR
T1 - FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model
AU - Lee, Richard S.
AU - Kuhr, Christian S.
AU - Sale, George E.
AU - Zellmer, Eustacia
AU - Hogan, William J.
AU - Storb, Rainer
AU - Little, Marie Térèse
PY - 2003/10/27
Y1 - 2003/10/27
N2 - Background. Acute graft-versus-host disease (GVHD) remains a significant impediment to successful hematopoietic stem-cell transplantation (HSCT). Here, we examined the effectiveness of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720), an immunosuppressant that retraffics activated lymphocytes to secondary lymphoid organs, for the treatment of acute GVHD in an established dog leukocyte antigen-nonidentical unrelated canine HSCT model. Methods. Dogs were given HSCT after conditioning with 920 cGy total body irradiation. The dogs received methotrexate 0.4 mg/kg/day on days 1, 3, 6, and 11 and FTY720 (5 mg/kg/day orally) after developing GVHD. Results. Five of six dogs achieved engraftment, developed acute GVHD, and were treated with FTY720. FTY720 resulted in a profound decrease in lymphocytes and a temporary mitigation of clinical GVHD; however, GVHD recurred in all dogs. Four of five dogs were euthanized because of severe GVHD and the fifth because of severe inanition associated with moderate GVHD. Conclusions. Compared with controls, treatment of GVHD with FTY720 did not control this complication or significantly increase survival.
AB - Background. Acute graft-versus-host disease (GVHD) remains a significant impediment to successful hematopoietic stem-cell transplantation (HSCT). Here, we examined the effectiveness of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720), an immunosuppressant that retraffics activated lymphocytes to secondary lymphoid organs, for the treatment of acute GVHD in an established dog leukocyte antigen-nonidentical unrelated canine HSCT model. Methods. Dogs were given HSCT after conditioning with 920 cGy total body irradiation. The dogs received methotrexate 0.4 mg/kg/day on days 1, 3, 6, and 11 and FTY720 (5 mg/kg/day orally) after developing GVHD. Results. Five of six dogs achieved engraftment, developed acute GVHD, and were treated with FTY720. FTY720 resulted in a profound decrease in lymphocytes and a temporary mitigation of clinical GVHD; however, GVHD recurred in all dogs. Four of five dogs were euthanized because of severe GVHD and the fifth because of severe inanition associated with moderate GVHD. Conclusions. Compared with controls, treatment of GVHD with FTY720 did not control this complication or significantly increase survival.
UR - http://www.scopus.com/inward/record.url?scp=0242363653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242363653&partnerID=8YFLogxK
U2 - 10.1097/01.TP.0000083891.14089.B8
DO - 10.1097/01.TP.0000083891.14089.B8
M3 - Article
C2 - 14578745
AN - SCOPUS:0242363653
SN - 0041-1337
VL - 76
SP - 1155
EP - 1158
JO - Transplantation
JF - Transplantation
IS - 8
ER -